Fat Loss & Metabolic Health

Retatrutide Dosage & Titration Chart: 5-30 mg Vials (2026)

A clinical, research-use-only reference for the documented Retatrutide protocol: the week-by-week titration ladder, reconstitution math for every vial size from 5 to…

Semaglutide Dosage and Titration: The Complete Schedule

A clinical-grade, research-use-only reference for the documented semaglutide weekly titration ladder (0.25 to 2.4 mg), with reconstitution math for 5, 10 and…

Tirzepatide Dosage and Titration: The Complete Schedule

Tirzepatide is a dual GIP + GLP-1 receptor agonist dosed once weekly and escalated slowly to protect gut tolerability. This complete research-use-only…

5-Amino-1MQ Dosage Per Day: Oral vs SubQ, and the Full Protocol

A complete, research-use-only 5-Amino-1MQ protocol: the documented per-day amounts for the 10 mg and 50 mg vials, the oral-vs-subcutaneous route question answered…

Retatrutide Side Effects & Safety: What the Clinical Research Shows

A sober, trial-sourced look at retatrutide's side-effect profile: the dose-dependent GI events, the resting heart-rate signal, discontinuation rates, and what long-term safety…

5-Amino-1MQ Results: What Research Shows & When (2026)

Every confident "week-by-week" 5-Amino-1MQ timeline online is extrapolated from an 11-day mouse study, with zero completed human trials. Here is what the…

Tesamorelin Benefits, Results and Side Effects: What the Trials Show

Tesamorelin is the rare research peptide with real human RCTs. Here is what randomized trials showed about visceral fat and liver fat,…

Retatrutide vs Semaglutide vs Tirzepatide: How the Research Compares (2026)

Two of these compounds are FDA-approved medicines with years of human data; the third is still investigational. Here is the honest three-way…

AOD-9604 and Fat Loss: What the Clinical Trials Actually Found

AOD-9604 is a fragment of human growth hormone that was developed as an obesity drug — and it failed. Roughly six human…

Orforglipron vs Peptide GLP-1 Agonists: What Actually Differs

The question at the head of this article carries a useful assumption worth surfacing before we go any further: that orforglipron and…